BiotechTube
MegaNano BioTech

MegaNano BioTech

Houston, United States· Est.
megananobiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

MegaNano BioTech is a private, preclinical-stage biotech developing a versatile dendritic cell vaccine platform and related therapeutic products. The company's lead programs target Alzheimer's and Parkinson's diseases, with exploratory work in lung cancer and malaria. It is currently seeking $5-10 million in investment to advance its second Alzheimer's vaccine candidate through IND-enabling studies and Phase I clinical trials, while also preparing to commercialize a nutraceutical nasal spray.

Neurodegenerative DiseasesOncologyInfectious Diseases

Technology Platform

Licensed dendritic cell vaccine platform using killed, lyophilized, antigen-sensitized dendritic cells from healthy donors. Designed to overcome immune tolerance, eliminate cold chain, and treat any antigen-related disease.

Opportunities

The company's lyophilized dendritic cell vaccine platform offers a unique solution for global, off-the-shelf cell therapy, addressing a major logistical hurdle in the field.
Significant near-term opportunities include securing $5-10M in investment to advance its lead Alzheimer's vaccine to the clinic and launching a nutraceutical nasal spray for rapid revenue generation.

Risk Factors

High risk of failure in translating preclinical vaccine data to human clinical efficacy and safety.
The company is heavily dependent on securing immediate investment to continue operations and fund IND-enabling studies.
It operates in intensely competitive therapeutic areas against large, well-resourced competitors.

Competitive Landscape

MegaNano BioTech competes in the crowded neurodegenerative and oncology immunotherapy spaces, facing large pharma and biotech firms with advanced clinical assets. Its key potential differentiation is the logistical advantage of a lyophilized, non-patient-specific dendritic cell vaccine, but it must first demonstrate clinical proof-of-concept to validate this approach against established modalities.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →